I am a
Home I AM A Search Login

Papers of the Week

Papers: 19 Nov 2022 - 25 Nov 2022

2022 Nov 17


Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.


Lipton RB, Pozo-Rosich P, Blumenfeld A, Li Y, Severt L, Stokes JT, Creutz L, Gandhi P, Dodick D
Neurology. 2022 Nov 17.
PMID: 36396451.


The oral calcitonin gene-related peptide receptor antagonist atogepant is indicated for the preventive treatment of episodic migraine. We evaluated changes in patient-reported outcomes with atogepant in adults with migraine.